cagrilintide semaglutide cagrisema phase 3 results 2024 2025 RESEARCH ARTICLE: Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 @SubodhVermaMD https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.125.26055 Novo Nordisk: Can CagriSema Show

Hims & Hers launches a $49 compounded semaglutide pill for weight loss, drawing sharp criticism and legal threats from Novo Nordisk over safety and approval concerns.

Semaglutide dosing for weight loss, explained: starting dose, titration chart in units, new 7.2 mg max, and what our Texas nurses recommend

Clinically Backed Prebiotic Fiber formulated to double GLP-1 levels, curb cravings, and promote regularity.

Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed for laboratory evaluation of endocrine signaling pathways